Sophia Abene

Study proves the role of harnessing CrAgSQ for management over the infection.

Vaccine designed to confront chronic HBV entering its first human clinical trial.

The impact of remdesivir across age groups.

Public health strategy in navigating flu season.

Customizing treatment strategies for enhanced outcomes and longevity.

Climate change's role in the expanding threat of vector-borne diseases.

Defense against omicron in HIV-positive patients post-COVID.

CDC addresses rising vector-borne diseases with an initiative to enhance public health protection.

Insights from CROI on the HepB-CpG vaccine trial.

Unraveling monocyte activation and the implications for cardiovascular risk

Insights from phase 3 study evaluating bulevirtide efficacy in coinfections.

Study shows high efficacy of a 4-week glecaprevir/pibrentasvir regimen for shorter, more manageable treatment duration.

The American Gastroenterological Association guidelines navigating fecal microbiota transplantation in clinical practice.

Study presented at CROI 2024 reveals chronic hepatitis B virus (HBV) infection heightens COVID-19 severity as vaccination reduces mortality and ICU demands in co-infected individuals.

Study presented at CROI 2024 reveals that the introduction of Doxycycline post-exposure prophylaxis (doxy-PEP) guidelines in San Francisco has significantly decreased the incidence of chlamydia and syphilis

Study dives into the complexities of using Oral Vancomycin Prophylaxis to combat Clostridioides difficile in hematopoietic stem cell transplantation recipients with insights from researcher Alexander Vartanov, MD.

Norovirus cases rise in the northeast and are spreading across the nation.

Novavax's Robert Walker, MD emphasizes protective health strategies highlighting the importance of COVID-19 vaccination for hypertensive individuals.

Promising oral antibiotic candidate for the treatment of uncomplicated urogenital gonorrhea

New insights challenge assumptions on SARS-CoV-2 immunity duration.

Study exposes the adherence gap in HCV direct-acting antiviral therapy among people who inject drugs.

Trial demonstrates promising results for oral treatment towards the disease's vector.

A rise in cases of the waterborne pathogen.

The American Gastroenterological Association recommends fecal microbiota-based therapies for recurrent or severe C difficile infections and other gastrointestinal issues.

CDC reveals trends in M pneumoniae infections before, during, and after the pandemic.

Shortage in hepatitis b virus (HBV) clinical trials within the WHO African region.

Innovative treatments, challenging prevention, and impact of climate change.

Phase 3 study shows ART treatment in maintaining viral load suppression

The mRNA-1647 vaccine demonstrated approximately a 50% efficacy against human cytomegalovirus (HCMV).

Study compares immune responses in cancer vs. non-cancer patients.